HZNP News and Press, Horizon Therapeutics Public Limited Company From 05/04/23

In accordance with Rule 2.12 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022 (the “ Irish Takeover Rules ”), Horizon confirms that, as of the close of business on March 31, 2023, Horizon’s issued ordinary share capital is comprised of 228,576,339 ordinary shar...

2023-05-03 18:27:10 ET Investors are often encouraged when one of their companies bulks up by acquiring a peer. But that sentiment can turn sour if the takeover target stumbles. This was the impetus behind Amgen 's (NASDAQ: AMGN) nearly 3% decline on the stock market Wednesday. ...

2023-05-03 12:11:48 ET Horizon Therapeutics ( NASDAQ: HZNP ) ticked down 0.7% following a Q1 miss on revenue and EPS, though the results miss is "irrelevant" given that the sale to Amgen is still likely to close, according to a UBS analyst. "We continue to view the sta...

2023-05-03 07:03:26 ET Horizon Therapeutics press release ( NASDAQ: HZNP ): Q1 Non-GAAP EPS of $0.83 misses by $0.37 . Revenue of $832.1M (-6.0% Y/Y) misses by $64.96M . For further details see: Horizon Therapeutics Non-GAAP EPS of $0.83 misses by $0.37, ...

First-Quarter 2023 Results: -- Net Sales of $832.1 Million -- -- GAAP Net Income of $54.7 Million; Adjusted EBITDA of $ 232.9 Million -- -- TEPEZZA® (teprotumumab-trbw) Net Sales of $405.3 Million -- -- KRYSTEXXA® (pegloticase injection) Net S...

2023-05-02 13:03:39 ET Horizon Therapeutics ( NASDAQ: HZNP ) is scheduled to announce Q1 earnings results on Wednesday, May 3rd, before market open. The consensus EPS Estimate is $1.20 (-10.4% Y/Y) and the consensus Revenue Estimate is $897.06M (+1.3% Y/Y). Over the la...

Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first patient has enrolled in a Phase 2 randomized placebo-controlled trial to evaluate its development-stage medicine daxdilimab, a potentially first-in-class, fully human monoclonal antibody targeting immunoglobulin-like transcript 7 (...

Horizon Therapeutics plc (Nasdaq: HZNP) today announced it ranked first in patient centricity, integrity, ease of relations and transparency in pricing by patient groups who worked with the company around the world. It ranks second in overall corporate reputation among these same groups. The resu...

2023-05-01 23:53:08 ET Summary My portfolio, built specifically for my retirement ~20 years from now, features growth, dividends, and risk stocks for a happy retirement. Great performances by Arrowhead Pharmaceuticals and Meta propelled my portfolio again to all-time highs and mar...

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the first patient has been enrolled in a Phase 3 clinical trial in Japan evaluating TEPEZZA for the treatment of adults with chronic Thyroid Eye Disease (TED) and low clinical activity score (CAS), which is a measure of disease activity...